Viridian Therapeutics: Key Catalysts Coming In The Second Half Of The Year [Seeking Alpha]
![Seeking Alpha](../../../Content/images/providers/Seeking Alpha.png)
Viridian Therapeutics, Inc. (VRDN)
Company Research
Source: Seeking Alpha
THRIVE-1 and THRIVE-2 phase 3 results of VRDN-001 in TED patients are the most important catalysts for the company this year. Matching Tepezza's efficacy and safety would be considered a win, but there is potential for better efficacy and safety. The phase 3 trial design for VRDN-003 addresses concerns about the company needing to conduct a phase 2 trial before going to phase 3. Anti-FcRn pipeline with VRDN-006 and VRDN-008 should get more visibility going forward with non-human primate data of VRDN-008 in 2H 2024 and phase 1 results of VRDN-006 in 2H 2025. Shares of Viridian Therapeutics, Inc. NASDAQ: VRDN ) have been under pressure since the start of the year, and the stock is down nearly 40% since my late 2023 article , despite the company executing well. The clinical Recommended For You Recommended For You About VRDN Stock More on VRDN Related Stocks Trending Analysis Trending News
Show less
Read more
Impact Snapshot
Event Time:
VRDN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRDN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRDN alerts
High impacting Viridian Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VRDN
News
- Are Analysts Bullish on Viridian Therapeutics, Inc. (VRDN) Right Now? [Yahoo! Finance]Yahoo! Finance
- Viridian (VRDN) Up 10% on Clinical Updates for Eye Disease Drug [Yahoo! Finance]Yahoo! Finance
- Viridian Therapeutics to begin Phase III trials of thyroid eye disease treatment [Yahoo! Finance]Yahoo! Finance
- Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $30.00 price target on the stock.MarketBeat
- Viridian Therapeutics, Inc. (NASDAQ: VRDN) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $29.00 price target on the stock.MarketBeat
VRDN
Earnings
- 5/8/24 - Beat
VRDN
Sec Filings
- 6/28/24 - Form 4
- 6/28/24 - Form 4
- 6/28/24 - Form 4
- VRDN's page on the SEC website